Effect of Palbociclib Plus Letrozole on Patient-Reported Health-Related Quality of Life: Extended Follow-Up of the PALOMA-2 Trial

The extended follow-up of the PALOMA-2 trial, with a median follow-up of 90 months, indicates that health-related quality of life (HRQoL) is maintained in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer receiving long-term treatment with palbociclib plus letrozole. The study involved 666 women, with 444 receiving palbociclib plus letrozole and 222 receiving placebo plus letrozole. No significant differences were found between the treatment groups in overall change from baseline in HRQoL scores. However, time to deterioration in quality of life was shorter for patients with disease progression. Side-effects and hair loss assessments favored the palbociclib plus letrozole arm, while no differences were observed for pain-related items.